Sign In
Last checked at 
17 Dec 2019 13:36
(AIM: SAR)
17 December 2019
Sareum Holdings plc
("Sareum" or the "Company")
Results of AGM
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting ("AGM") today and all resolutions were duly passed on a poll. Details of the proxy voting are shown in the table below.
In addition, the Board of Directors confirmed at the AGM that all executive and non-executive directors had entered into a salary deferral scheme, whereby 33% of directors' salaries are being deferred until further notice, as part of the Company's efforts to maximise its cash resources.
Ordinary resolutions | Votes For | % | Votes Against | % | Votes Total | % of ISC Voted | Votes Withheld |
1. Receive the Annual report and accounts for the Company | 339,577,999 | 99.65 | 1,187,470 | 0.35 | 340,765,469 | 11.09% | 2,191,331 |
2. Approve the Directors' Remuneration Report | 327,161,863 | 95.45 | 15,603,606 | 4.55 | 342,765,469 | 11.16% | 191,331 |
3. Re-elect Dr John Reader as a director | 339,084,553 | 99.45 | 1,872,247 | 0.55 | 340,956,800 | 11.10% | 2,000,000 |
4. Appoint Shipleys LLP as auditor | 340,472,792 | 99.86 | 484,008 | 0.14 | 340,956,800 | 11.10% | 2,000,000 |
5. Directors' authority to allot new shares | 301,404,835 | 88.77 | 38,112,158 | 11.23 | 339,516,993 | 11.05% | 3,439,807 |
Special Resolution | |||||||
6. Disapplication of pre-emption rights | 298,109,670 | 87.51 | 42,545,299 | 12.49 | 340,654,969 | 11.09% | 2,301,831 |
ISC - Issued Share Capital
The full text of each of the resolutions is set out in the Notice of AGM, available on the Company's website (www.sareum.com)
This announcement contains inside information for the purposes of the market abuse regulation (EU No. 596/2014) ("MAR").
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
Strand Hanson Limited (Nominated Adviser) | |
James Dance / Richard Tulloch | 020 7409 3494 |
Hybridan LLP (Nominated Broker) | |
Claire Noyce / John Beresford-Peirse | 020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) | |
Mark Swallow / David Dible | 020 7638 9571 |
Notes for editors:
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a $328.5m plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.
- Ends -
Follow the stocks
